US › Healthcare

Cabaletta Bio Inc (CABA)

US · Healthcare · Biotechnology

$2.77+2.97%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-43.5M

Profit YoY

-21.1%

EPS

$-0.39

EPS estimate

$-0.39

EPS came in at -0.39 against a street estimate of -0.39 — a beat of 0.0%.

Key statistics

Market cap

$437.0M

Forward P/E

0.0

P/B

4.23

Book value

$0.93

EPS (TTM)

$-1.78

52-week high

$4.23

52-week low

$1.26

50-day MA

$3.08

200-day MA

$2.86

Beta

3.26

Analyst view

Analysts rate Cabaletta Bio Inc a strong buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $13.38.

Shareholding

Insiders

1.00%

Institutions

62.59%

Largest institutional holders

Fund	Stake
T. Rowe Price Investment Management,Inc.	9.95%
Bain Capital Life Sciences Investors, LLC	8.69%
Jennison Associates LLC	8.06%
Adage Capital Partners Gp LLC	7.93%
Millennium Management LLC	5.30%
Cormorant Asset Management, LLC	4.94%
Vanguard Capital Management, LLC	3.62%
Two Sigma Investments LLC	2.24%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cabaletta Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.